Company intelligence / Profile preview
Linno Pharmaceuticals
Shanghai, Shanghai, Chinalinnopharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Linno Pharmaceuticals has developed proprietary platforms enabling long half-life biologics and efficient blood-brain barrier penetration. Its lead programs include a recombinant arylsulfatase A enzyme for MLD with orphan drug designation from the FDA, as well as several antibody/nanobody-based therapeutics targeting rare neurological and immune diseases. Most programs are in preclinical or early clinical stages; no late-stage or commercialized products reported as of May 2025.
- Therapeutic areas
- OncologyOphthalmologyNephrologyNeurology
- Modalities
- AntibodiesNanobodiesRecombinant proteinsEnzymesAntibody fusion proteins
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
Beyond the preview
Go deeper on Linno Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Linno Pharmaceuticals.